Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

ABSTRACT: In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count <200×10⁹/l (p=0.028), and a time-interval between MF diagnosis and RUX start >2 years (p=0.048). Also, patients trea

SUBMITTER: Palandri F 

PROVIDER: S-EPMC5668021 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature